EUVIMEDEUVIMED entdecken
Crossref

Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer

Ze-Wei Cheng, Meng Wei, Yuan Zhang, Yi-Ze Liang, Wei-Bo Cao, Ru-Dong Zhao, Zhi-Bo Yan, Guo-Rui Sun, Xiao-Han Cui, Wen-Bin Yu

World Journal of Gastroenterology · 14.01.2027 · 33 (2)

DOI: 10.3748/wjg.122397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.01.2027. Verfasst von Ze-Wei Cheng und 9 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Neoadjuvant chemotherapy remains the standard for locally advanced gastric cancer (LAGC), yet outcomes remain suboptimal. Programmed cell death protein-1 inhibitors and apatinib have been used individually with chemotherapy for the treatment of LAGC, but the clinical benefit of programmed cell death protein-1 inhibitors plus apatinib and chemotherapy (PAC) as a neoadjuvant strategy requires comprehensive evaluation. AIM To evaluate the surgical safety and efficacy of PAC vs preoperative chemotherapy for LAGC. METHODS This retrospective study included 292 patients with LAGC who received either PAC (n = 92) or preoperative chemotherapy (n = 200) followed by radical gastrectomy between January 2019 and December 2022. Tumor regression, surgical outcomes, postoperative recovery, and survival were compared between groups. Subgroup analysis was performed to evaluate the role of indocyanine green (ICG) fluorescence guidance. Overall survival, progression-free survival, and disease-free survival were estimated using Kaplan-Meier method, and independent prognostic factors were identified by the Cox proportional hazards regression model. RESULTS The PAC group demonstrated significantly higher pathological complete response rates (28.3% vs 6.5%, P < 0.001) and major pathological response rates (45.7% vs 27.5%, P = 0.002). Despite the PAC regimen increased intraoperative blood loss (100 mL vs 80 mL, P < 0.001), R0 resection rates (92.4% vs 91.0%, P = 0.693) and postoperative complications (23.9% vs 28.0%, P = 0.463) were comparable. ICG fluorescence guidance in the PAC group reduced the open conversion rate (0% vs 19.4%, P = 0.015) and increased the lymph node yield (32 vs 24, P = 0.004). The PAC regimen was significantly associated with prolonged survival outcomes (log-rank P < 0.001) and was an independent prognostic predictor in multivariate analyses (P < 0.05). CONCLUSION The PAC regimen significantly improved the pathological response and survival of patients with LAGC, without compromising surgical safety. ICG fluorescence guidance along with the PAC regimen may further optimize surgical outcomes.

Zitieren

APA

Cheng, Z., Wei, M., Zhang, Y., Liang, Y., Cao, W., Zhao, R., Yan, Z., Sun, G., Cui, X., & Yu, W. (2027). Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World Journal of Gastroenterology, 33(2). https://doi.org/10.3748/wjg.122397

Vancouver

Cheng Z, Wei M, Zhang Y, Liang Y, Cao W, Zhao R, et al. Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer. World Journal of Gastroenterology. 2027;33(2). doi:10.3748/wjg.122397

BibTeX
@article{Cheng2027,
  author = {Cheng, Ze-Wei and Wei, Meng and Zhang, Yuan and Liang, Yi-Ze and Cao, Wei-Bo and Zhao, Ru-Dong and Yan, Zhi-Bo and Sun, Guo-Rui and Cui, Xiao-Han and Yu, Wen-Bin},
  title = {Surgical safety and efficacy of neoadjuvant immunotherapy plus apatinib and chemotherapy in locally advanced gastric cancer},
  journal = {World Journal of Gastroenterology},
  year = {2027},
  volume = {33},
  number = {2},
  doi = {10.3748/wjg.122397}
}
Kostenlos starten →